VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
tenofovir/emtricitabine/rilpivirine
Preclinical
Small molecule
M
Mahidol University
1
Indications
2
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Itching
Completed
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Itching
Preclinical
Completed
Clinical
Trials by Indication
[1]
Itching
1 trial
Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological Suppression
Completed
·
M
Mahidol University
·
N/A
·
NCT03251690
·
246 enrolled
Toxicity
1 trial
A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine
Completed
·
S
St Stephens Aids Trust
·
Phase 3
·
NCT01701882
·
40 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
2 trial records for tenofovir/emtricitabine/rilpivirine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
tenofovir/emtricitabine/rilpivirine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for tenofovir/emtricitabine/rilpivirine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Mahidol University company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Preclinical
[1]
Company
M
Mahidol University
Related News